BRNS
Barinthus Biotherapeutics PLC - ADR

171
Mkt Cap
$29.03M
Volume
36,095.00
52W High
$2.92
52W Low
$0.64
PE Ratio
-0.38
BRNS Fundamentals
Price
$0.7741
Prev Close
$0.711
Open
$0.734
50D MA
$1.17
Beta
0.72
Avg. Volume
105,431.22
EPS (Annual)
-$1.55
P/B
0.34
Rev/Employee
$142,621.89
Loading...
Loading...
News
all
press releases
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to...
PR Newswire·7d ago
News Placeholder
More News
News Placeholder
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA, HFWA, BRNS, and FITB $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-CMA...
PR Newswire·7d ago
News Placeholder
Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights
Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages NIC, AKRO, BRNS Shareholders to Contact the Firm to Discuss Their...
PR Newswire·14d ago
News Placeholder
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF, AKRO, NIC, and BRNS $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger-CRTAF...
PR Newswire·16d ago
News Placeholder
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with...
PR Newswire·1mo ago
News Placeholder
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates SWKH, ETNB, BRNS, VRNT on Behalf of...
PR Newswire·1mo ago
News Placeholder
Barinthus Biotherapeutics To Merge With Privately-Held Clywedog Therapeutics
Under the deal, Barinthus Bio shareholders will receive one share of common stock in the new combined company for each American Depositary Share or ordinary share they own.
Stocktwits·2mo ago
News Placeholder
Barclays Remains a Buy on Barinthus Biotherapeutics (BRNS)
Barclays analyst Carter Gould maintained a Buy rating on Barinthus Biotherapeutics (BRNS Research Report) today and set a price target of $3.00...
TipRanks Financial Blog·1y ago
News Placeholder
Infection-Focused Barinthus Bio's VTP-200 Data Underwhelming: Analyst Weighs On Mixed Perspectives
Explore the latest findings from Barinthus Biotherapeutics on VTP-200's performance in the APOLLO trial for low-grade cervical lesions linked to persistent hrHPV infection. Positive trends were...
Benzinga·2y ago
News Placeholder
Barinthus Biotherapeutics (NASDAQ:BRNS) PT Lowered to $8.00 at HC Wainwright
Barinthus Biotherapeutics (NASDAQ:BRNS Free Report) had its price objective cut by HC Wainwright from $15.00 to $8.00 in a research report released on Thursday, Benzinga reports. They...
Ticker Report·2y ago

Latest BRNS News

View

Advertisement|Remove ads.

Advertisement|Remove ads.